undamentalytics Newsletter
Sign in

Immunome Inc. balance sheet

At the end of fiscal 2025, Immunome Inc. had total assets of $683m, total liabilities of $48.8m and shareholders' equity of $634m. It held $653m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents99143653218
Total current assets145221661538
Total assets149240683565
Accounts payable31436
Deferred revenue (current)1070—
Total current liabilities22544536
Total debt0000
Total liabilities29594940
Shareholders' equity120181634525
Shares outstanding—64m—113m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunome Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunome Inc.